Insomnia Pharmacological Treatment Market - Global Forecast 2026-2032

The Insomnia Pharmacological Treatment Market is projected to reach USD 3.53 Billion in 2026. It is expected to continue growing at a CAGR of 5.96%, reaching USD 5.01 Billion by 2032.

Insomnia pharmacological treatment is evolving as clinicians, payers, and regulators balance the need for effective sleep initiation and sleep maintenance therapies with safety, next-day functioning, dependence risk, and long-term patient outcomes. The treatment landscape includes prescription hypnotics, benzodiazepine receptor agonists, melatonin receptor agonists, orexin receptor antagonists, sedating antidepressants used in selected cases, and regionally available agents supported by local regulatory pathways. Clinical guidance continues to emphasize accurate diagnosis, assessment of comorbid psychiatric and medical conditions, medication review, and the use of cognitive behavioral therapy for insomnia as a foundational intervention, with pharmacotherapy considered when symptoms are clinically significant, persistent, or inadequately controlled. Demand for evidence-based insomnia medication is reinforced by the high burden of sleep disorders, aging populations, shift work, digital lifestyle disruption, and the increasing recognition that untreated insomnia is associated with impaired quality of life, workplace productivity loss, accident risk, and greater healthcare utilization. SEO-relevant themes shaping executive priorities include insomnia drugs, sleep disorder treatment, prescription sleep aids, orexin receptor antagonists, chronic insomnia management, pharmacological sleep therapy, hypnotic medications, and patient-centered sleep medicine.

Transformative Shifts in the Insomnia Treatment Landscape

The insomnia pharmacological treatment landscape is undergoing transformative shifts driven by safer mechanism-based therapies, tighter prescribing expectations, and a stronger focus on individualized care. Traditional sedative-hypnotic prescribing is being reassessed due to concerns regarding tolerance, dependence, falls, cognitive effects, respiratory comorbidity, and next-day psychomotor impairment, particularly among older adults and patients with polypharmacy. At the same time, orexin pathway modulation has expanded clinical interest because it targets wakefulness regulation rather than broad central nervous system depression, supporting a differentiated approach to chronic insomnia therapy. Regulatory agencies and clinical societies increasingly encourage careful benefit-risk evaluation, short-duration use where appropriate, patient counseling, and monitoring for complex sleep behaviors and residual sedation. Digital therapeutics, telehealth-based sleep assessment, wearable sleep data, and pharmacy-led medication management are also changing treatment access and adherence monitoring. These shifts are moving the sector from symptom suppression toward precision sleep care, where pharmacological treatment is integrated with behavioral intervention, comorbidity management, and real-world safety surveillance.

Cumulative Impact of Artificial Intelligence

Artificial intelligence is beginning to influence insomnia pharmacological treatment through improved screening, clinical decision support, medication safety analytics, and real-world evidence generation. AI-enabled tools can analyze electronic health records, prescription histories, wearable-derived sleep patterns, and patient-reported outcomes to help identify insomnia phenotypes, detect contraindications, flag drug-drug interactions, and support appropriate therapy selection. In research settings, machine learning can accelerate signal detection in pharmacovigilance databases, identify predictors of treatment response, and support trial design by improving patient stratification and endpoint measurement. AI is also enhancing remote monitoring by connecting digital sleep diaries, actigraphy, and adherence data, enabling clinicians to refine treatment plans more quickly. However, adoption must be governed by clinical validation, transparency, privacy protection, bias mitigation, and alignment with prescribing standards. The cumulative impact of artificial intelligence is not the replacement of clinical judgment, but the strengthening of safer, more personalized, and evidence-driven insomnia medication management.

Key Regional Insights Across Global Insomnia Treatment

In Asia-Pacific, insomnia pharmacological treatment is shaped by large urban populations, high work intensity, aging demographics in Japan, South Korea, China, and Australia, and growing awareness of sleep disorders across primary care and specialty channels. Regulatory and reimbursement pathways differ widely, creating variation in access to newer hypnotic classes and continued use of established therapies. North America demonstrates strong clinical adoption of guideline-informed insomnia management, broad availability of prescription sleep medications, and heightened scrutiny of controlled substances, medication safety, and older-adult prescribing. In Latin America, access patterns are influenced by public and private healthcare fragmentation, specialist availability, and the need for affordable sleep disorder treatment in countries with rising mental health and chronic disease burdens. Europe is characterized by structured pharmacovigilance, national prescribing guidance, and emphasis on nonpharmacological first-line care, while still maintaining demand for targeted pharmacotherapy in persistent insomnia. The Middle East is seeing increasing recognition of sleep disorders alongside lifestyle changes, metabolic disease prevalence, and expanding private healthcare infrastructure. Across Africa, insomnia treatment access remains uneven, with opportunities tied to primary care strengthening, mental health integration, essential medicine availability, and better diagnosis of sleep disorders in populations affected by stress, urbanization, and comorbid disease.

Key Group Insights for Insomnia Pharmacological Treatment

ASEAN markets reflect diverse healthcare maturity, with insomnia pharmacological treatment adoption influenced by urbanization, workplace stress, private pharmacy access, and growing investment in mental health services across major economies. The GCC is marked by expanding specialty care, high digital health readiness, and increasing attention to sleep disorders associated with obesity, diabetes, shift work, and lifestyle-related risk factors. Within the European Union, harmonized medicine safety expectations coexist with country-specific reimbursement and prescribing practices, supporting careful use of insomnia drugs and ongoing preference for behavioral treatment integration. BRICS countries present substantial clinical need due to large populations, rising chronic disease burden, and expanding healthcare access, while also showing variability in regulatory capacity, affordability, and availability of newer sleep medications. G7 countries generally show higher clinical guideline penetration, stronger pharmacovigilance infrastructure, and broader availability of advanced therapies, making medication optimization, deprescribing, and real-world outcomes central priorities. NATO member countries overlap significantly with advanced healthcare systems in North America and Europe, where insomnia treatment strategies are increasingly linked to military readiness, veteran health, stress-related sleep disturbance, and safe prescribing in populations with mental health comorbidities.

Key Country Insights in Insomnia Pharmacological Treatment

The United States has a highly developed insomnia treatment environment with broad prescription availability, strong direct clinical awareness, and ongoing concern regarding sedative safety, controlled-substance use, and treatment of insomnia comorbid with anxiety, depression, pain, and sleep apnea. Canada emphasizes evidence-based prescribing, public health awareness, and cautious medication use, particularly among older adults. Mexico and Brazil show growing demand for sleep disorder treatment as urban stress, mental health burden, and private healthcare access expand, though affordability and specialist distribution remain important considerations. In the United Kingdom, insomnia management is strongly influenced by national clinical guidance, primary care gatekeeping, and emphasis on behavioral interventions before or alongside pharmacotherapy. Germany, France, Italy, and Spain combine mature regulatory oversight with country-specific prescribing traditions and reimbursement approaches, supporting careful selection of hypnotic medications for chronic insomnia and short-term sleep disturbance. Russia presents demand linked to stress-related sleep disorders and neurological care pathways, with local access dynamics shaping pharmacological choices. China and India carry large unmet clinical needs due to population scale, urbanization, aging, and increasing recognition of sleep health, while access, diagnosis rates, and affordability vary across regions. Japan has significant relevance due to its aging population, high sleep complaint prevalence, and strong attention to medication safety in older adults. Australia reflects guideline-driven care, increasing use of digital health support, and careful monitoring of sedative-hypnotic prescribing. South Korea combines advanced healthcare access, high work-related stress exposure, and growing sleep medicine awareness, supporting demand for clinically differentiated insomnia therapies.

Actionable Recommendations for Industry Leaders

Industry leaders should prioritize evidence generation that demonstrates clinically meaningful improvements in sleep onset, sleep maintenance, next-day functioning, safety, and patient-reported quality of life. Development strategies should focus on differentiated mechanisms, lower abuse potential, favorable older-adult safety profiles, and compatibility with comorbidity-driven prescribing. Stakeholders should strengthen real-world evidence programs, pharmacovigilance, and post-authorization safety monitoring to address residual sedation, falls, cognitive effects, complex sleep behaviors, and drug-drug interactions. Commercial and medical teams should align education with clinical guidelines, emphasizing appropriate diagnosis, patient selection, duration of therapy, tapering strategies, and integration with cognitive behavioral therapy for insomnia. Access strategies should reflect country-level reimbursement realities, affordability constraints, and the role of primary care physicians, psychiatrists, neurologists, geriatricians, pulmonologists, and pharmacists. Digital sleep tools and AI-enabled support should be deployed only where clinically validated, privacy-protective, and capable of improving adherence, monitoring, or treatment personalization. Leaders should also invest in inclusive research across older adults, women, shift workers, patients with psychiatric comorbidity, and populations historically underrepresented in sleep medicine studies.

Research Methodology

This executive summary is developed through a structured secondary research approach using verified public-domain and authoritative sources, including regulatory agency communications, clinical practice guidelines, peer-reviewed medical literature, pharmacovigilance references, public health publications, and internationally recognized healthcare policy resources. The methodology emphasizes data triangulation across clinical evidence, regulatory standards, treatment guidelines, and regional healthcare access indicators. Insights were assessed for relevance to insomnia pharmacological treatment, including medication classes, safety considerations, prescribing practices, patient populations, comorbidity patterns, and evolving digital health applications. Regional, group, and country-level narratives were synthesized to reflect documented healthcare system characteristics, regulatory maturity, demographic drivers, and treatment access dynamics without using market estimation, market sizing, market share, or forecasting. The analysis prioritizes reproducibility, source credibility, clinical validity, and consistency with current evidence-based sleep medicine practices.

Conclusion

Insomnia pharmacological treatment is entering a more selective, safety-conscious, and patient-centered phase. The sector is being shaped by the shift from broad sedative approaches toward mechanism-informed therapies, stronger integration with behavioral care, and wider use of real-world safety monitoring. Artificial intelligence and digital sleep technologies can improve screening, adherence tracking, and individualized prescribing, but their value depends on clinical validation and responsible governance. Regional differences in access, reimbursement, regulation, and clinical practice will continue to influence therapy adoption, while countries with aging populations, high stress exposure, and strong sleep medicine infrastructure are likely to remain central to innovation and evidence generation. For industry leaders, the most defensible path forward is to combine differentiated pharmacology with rigorous safety data, guideline-aligned education, equitable access planning, and measurable improvements in patient outcomes.

Additional Product Information:

Purchase of this report includes 1 year online access with quarterly updates.
This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

1. Preface

1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders

2. Research Methodology

2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations

3. Executive Summary

3.1. Introduction
3.2. CXO Perspective
3.3. Market Size & Growth Trends
3.4. New Revenue Opportunities
3.5. Next-Generation Business Models
3.6. Industry Roadmap

4. Market Overview

4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Market Dynamics
4.3.1. Key Drivers
4.3.2. Key Restraints
4.3.3. Key Opportunities
4.3.4. Key Challenges
4.4. Porter’s Five Forces Analysis
4.5. PESTLE Analysis
4.6. Market Outlook
4.6.1. Near-Term Market Outlook (0-2 Years)
4.6.2. Medium-Term Market Outlook (3-5 Years)
4.6.3. Long-Term Market Outlook (5-10 Years)
4.7. Go-to-Market Strategy

5. Market Insights

5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Insomnia Pharmacological Treatment Market, by Drug Class

7.1. Introduction
7.2. Benzodiazepines
7.2.1. Estazolam
7.2.2. Temazepam
7.2.3. Triazolam
7.3. Melatonin Receptor Agonists
7.3.1. Agomelatine
7.3.2. Melatonin
7.3.3. Ramelteon
7.4. Non Benzodiazepine Hypnotics
7.4.1. Eszopiclone
7.4.2. Zaleplon
7.4.3. Zolpidem
7.4.3.1. Extended Release
7.4.3.2. Immediate Release
7.5. Orexin Receptor Antagonists
7.5.1. Lemborexant
7.5.2. Suvorexant
7.6. Sedating Antidepressants
7.6.1. Doxepin
7.6.2. Trazodone

8. Insomnia Pharmacological Treatment Market, by Dosage Form

8.1. Introduction
8.2. Capsules
8.2.1. Hard Gelatin
8.2.2. Soft Gelatin
8.3. Oral Suspension
8.4. Tablets
8.4.1. Controlled Release
8.4.2. Immediate Release

9. Insomnia Pharmacological Treatment Market, by Sleep Disorder Type

9.1. Introduction
9.2. Sleep Onset Insomnia
9.3. Sleep Maintenance Insomnia
9.4. Mixed Insomnia

10. Insomnia Pharmacological Treatment Market, by Distribution Channel

10.1. Introduction
10.2. Hospital Pharmacy
10.2.1. Private
10.2.2. Public
10.3. Online Pharmacy
10.3.1. Marketplaces
10.3.2. Specialty Online Pharmacies
10.4. Retail Pharmacy
10.4.1. Chain
10.4.2. Independent

11. Insomnia Pharmacological Treatment Market, by End User

11.1. Introduction
11.2. Homecare Settings
11.2.1. Assisted Living
11.2.2. Private Homecare
11.3. Hospitals
11.3.1. General Hospitals
11.3.2. Psychiatric Hospitals
11.4. Specialty Clinics
11.4.1. Outpatient Clinics
11.4.2. Sleep Disorder Clinics

12. Insomnia Pharmacological Treatment Market, by Region

12.1. Asia-Pacific
12.2. Europe
12.3. North America
12.4. Latin America
12.5. Africa
12.6. Middle East

13. Insomnia Pharmacological Treatment Market, by Group

13.1. NATO
13.2. G7
13.3. BRICS
13.4. European Union
13.5. ASEAN
13.6. GCC

14. Insomnia Pharmacological Treatment Market, by Country

14.1. China
14.2. United States
14.3. Japan
14.4. India
14.5. Germany
14.6. United Kingdom
14.7. Australia
14.8. France
14.9. South Korea
14.10. Italy
14.11. Canada
14.12. Russia
14.13. Brazil
14.14. Mexico
14.15. Spain

15. Competitive Landscape

15.1. Market Share Analysis, 2025
15.2. FPNV Positioning Matrix, 2025
15.3. Market Concentration Analysis, 2025
15.3.1. Concentration Ratio (CR)
15.3.2. Herfindahl Hirschman Index (HHI)
15.4. Recent Developments & Impact Analysis, 2025
15.5. Product Portfolio Analysis, 2025
15.6. Benchmarking Analysis, 2025

16. Company Profiles

16.1. Academics Pharmaceuticals Inc
16.2. Alembic Pharmaceuticals Ltd
16.3. Alkem Laboratories Ltd
16.4. Astellas Pharma Inc
16.5. Aurobindo Pharma Ltd
16.6. Avadel Pharmaceuticals plc
16.7. Bayer AG
16.8. Cipla Ltd
16.9. Currax Pharmaceuticals LLC
16.10. Dr Reddy's Laboratories Ltd
16.11. Eisai Co Ltd
16.12. GlaxoSmithKline plc
16.13. Glenmark Pharmaceuticals Ltd
16.14. H Lundbeck A/S
16.15. Idorsia Ltd
16.16. Jazz Pharmaceuticals plc
16.17. Lupin Ltd
16.18. Mankind Pharma Ltd
16.19. Merck & Co Inc
16.20. Novartis AG
16.21. Pfizer Inc
16.22. Procter & Gamble Health Ltd
16.23. Sanofi SA
16.24. Sumitomo Pharma Co Ltd
16.25. Sun Pharmaceutical Industries Ltd
16.26. Takeda Pharmaceutical Company Limited
16.27. Teva Pharmaceutical Industries Ltd
16.28. Torrent Pharmaceuticals Ltd
16.29. Viatris Inc
16.30. Zydus Lifesciences Ltd

List of Figures

FIGURE 1. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET, YEARS CONSIDERED FOR THE STUDY
FIGURE 2. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET, RESEARCH DESIGN
FIGURE 3. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET, RESEARCH FRAMEWORK
FIGURE 4. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET, DATA TRIANGULATION
FIGURE 5. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 6. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY DRUG CLASS, 2025 VS 2032 (%)
FIGURE 7. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY DRUG CLASS, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 8. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY DOSAGE FORM, 2025 VS 2032 (%)
FIGURE 9. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY DOSAGE FORM, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 10. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY SLEEP DISORDER TYPE, 2025 VS 2032 (%)
FIGURE 11. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY SLEEP DISORDER TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 12. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2032 (%)
FIGURE 13. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 14. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY END USER, 2025 VS 2032 (%)
FIGURE 15. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 16. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 17. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 18. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 19. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 20. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
FIGURE 21. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 22. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SHARE, BY KEY PLAYER, 2025
FIGURE 23. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET, FPNV POSITIONING MATRIX, BY KEY PLAYER, 2025

List of Tables

TABLE 1. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SEGMENTATION & COVERAGE
TABLE 2. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 3. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 4. GLOBAL BENZODIAZEPINES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 5. GLOBAL BENZODIAZEPINES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 6. GLOBAL BENZODIAZEPINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 7. GLOBAL ESTAZOLAM MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 8. GLOBAL ESTAZOLAM MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 9. GLOBAL ESTAZOLAM MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 10. GLOBAL TEMAZEPAM MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 11. GLOBAL TEMAZEPAM MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 12. GLOBAL TEMAZEPAM MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 13. GLOBAL TRIAZOLAM MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 14. GLOBAL TRIAZOLAM MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 15. GLOBAL TRIAZOLAM MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 16. GLOBAL MELATONIN RECEPTOR AGONISTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 17. GLOBAL MELATONIN RECEPTOR AGONISTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 18. GLOBAL MELATONIN RECEPTOR AGONISTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 19. GLOBAL AGOMELATINE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 20. GLOBAL AGOMELATINE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 21. GLOBAL AGOMELATINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 22. GLOBAL MELATONIN MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 23. GLOBAL MELATONIN MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 24. GLOBAL MELATONIN MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 25. GLOBAL RAMELTEON MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 26. GLOBAL RAMELTEON MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 27. GLOBAL RAMELTEON MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 28. GLOBAL NON BENZODIAZEPINE HYPNOTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 29. GLOBAL NON BENZODIAZEPINE HYPNOTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 30. GLOBAL NON BENZODIAZEPINE HYPNOTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 31. GLOBAL ESZOPICLONE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 32. GLOBAL ESZOPICLONE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 33. GLOBAL ESZOPICLONE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 34. GLOBAL ZALEPLON MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 35. GLOBAL ZALEPLON MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 36. GLOBAL ZALEPLON MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 37. GLOBAL ZOLPIDEM MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 38. GLOBAL ZOLPIDEM MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 39. GLOBAL ZOLPIDEM MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 40. GLOBAL EXTENDED RELEASE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 41. GLOBAL EXTENDED RELEASE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 42. GLOBAL EXTENDED RELEASE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 43. GLOBAL IMMEDIATE RELEASE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 44. GLOBAL IMMEDIATE RELEASE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 45. GLOBAL IMMEDIATE RELEASE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 46. GLOBAL OREXIN RECEPTOR ANTAGONISTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 47. GLOBAL OREXIN RECEPTOR ANTAGONISTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 48. GLOBAL OREXIN RECEPTOR ANTAGONISTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 49. GLOBAL LEMBOREXANT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 50. GLOBAL LEMBOREXANT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 51. GLOBAL LEMBOREXANT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 52. GLOBAL SUVOREXANT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 53. GLOBAL SUVOREXANT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 54. GLOBAL SUVOREXANT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 55. GLOBAL SEDATING ANTIDEPRESSANTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 56. GLOBAL SEDATING ANTIDEPRESSANTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 57. GLOBAL SEDATING ANTIDEPRESSANTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 58. GLOBAL DOXEPIN MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 59. GLOBAL DOXEPIN MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 60. GLOBAL DOXEPIN MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 61. GLOBAL TRAZODONE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 62. GLOBAL TRAZODONE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 63. GLOBAL TRAZODONE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 64. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
TABLE 65. GLOBAL CAPSULES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 66. GLOBAL CAPSULES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 67. GLOBAL CAPSULES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 68. GLOBAL HARD GELATIN MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 69. GLOBAL HARD GELATIN MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 70. GLOBAL HARD GELATIN MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 71. GLOBAL SOFT GELATIN MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 72. GLOBAL SOFT GELATIN MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 73. GLOBAL SOFT GELATIN MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 74. GLOBAL ORAL SUSPENSION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 75. GLOBAL ORAL SUSPENSION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 76. GLOBAL ORAL SUSPENSION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 77. GLOBAL TABLETS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 78. GLOBAL TABLETS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 79. GLOBAL TABLETS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 80. GLOBAL CONTROLLED RELEASE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 81. GLOBAL CONTROLLED RELEASE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 82. GLOBAL CONTROLLED RELEASE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 83. GLOBAL IMMEDIATE RELEASE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 84. GLOBAL IMMEDIATE RELEASE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 85. GLOBAL IMMEDIATE RELEASE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 86. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY SLEEP DISORDER TYPE, 2018-2032 (USD MILLION)
TABLE 87. GLOBAL SLEEP ONSET INSOMNIA MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 88. GLOBAL SLEEP ONSET INSOMNIA MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 89. GLOBAL SLEEP ONSET INSOMNIA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 90. GLOBAL SLEEP MAINTENANCE INSOMNIA MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 91. GLOBAL SLEEP MAINTENANCE INSOMNIA MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 92. GLOBAL SLEEP MAINTENANCE INSOMNIA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 93. GLOBAL MIXED INSOMNIA MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 94. GLOBAL MIXED INSOMNIA MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 95. GLOBAL MIXED INSOMNIA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 96. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 97. GLOBAL HOSPITAL PHARMACY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 98. GLOBAL HOSPITAL PHARMACY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 99. GLOBAL HOSPITAL PHARMACY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 100. GLOBAL PRIVATE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 101. GLOBAL PRIVATE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 102. GLOBAL PRIVATE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 103. GLOBAL PUBLIC MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 104. GLOBAL PUBLIC MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 105. GLOBAL PUBLIC MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 106. GLOBAL ONLINE PHARMACY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 107. GLOBAL ONLINE PHARMACY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 108. GLOBAL ONLINE PHARMACY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 109. GLOBAL MARKETPLACES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 110. GLOBAL MARKETPLACES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 111. GLOBAL MARKETPLACES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 112. GLOBAL SPECIALTY ONLINE PHARMACIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 113. GLOBAL SPECIALTY ONLINE PHARMACIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 114. GLOBAL SPECIALTY ONLINE PHARMACIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 115. GLOBAL RETAIL PHARMACY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 116. GLOBAL RETAIL PHARMACY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 117. GLOBAL RETAIL PHARMACY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 118. GLOBAL CHAIN MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 119. GLOBAL CHAIN MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 120. GLOBAL CHAIN MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 121. GLOBAL INDEPENDENT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 122. GLOBAL INDEPENDENT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 123. GLOBAL INDEPENDENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 124. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 125. GLOBAL HOMECARE SETTINGS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 126. GLOBAL HOMECARE SETTINGS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 127. GLOBAL HOMECARE SETTINGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 128. GLOBAL ASSISTED LIVING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 129. GLOBAL ASSISTED LIVING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 130. GLOBAL ASSISTED LIVING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 131. GLOBAL PRIVATE HOMECARE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 132. GLOBAL PRIVATE HOMECARE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 133. GLOBAL PRIVATE HOMECARE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 134. GLOBAL HOSPITALS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 135. GLOBAL HOSPITALS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 136. GLOBAL HOSPITALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 137. GLOBAL GENERAL HOSPITALS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 138. GLOBAL GENERAL HOSPITALS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 139. GLOBAL GENERAL HOSPITALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 140. GLOBAL PSYCHIATRIC HOSPITALS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 141. GLOBAL PSYCHIATRIC HOSPITALS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 142. GLOBAL PSYCHIATRIC HOSPITALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 143. GLOBAL SPECIALTY CLINICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 144. GLOBAL SPECIALTY CLINICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 145. GLOBAL SPECIALTY CLINICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 146. GLOBAL OUTPATIENT CLINICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 147. GLOBAL OUTPATIENT CLINICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 148. GLOBAL OUTPATIENT CLINICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 149. GLOBAL SLEEP DISORDER CLINICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 150. GLOBAL SLEEP DISORDER CLINICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 151. GLOBAL SLEEP DISORDER CLINICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 152. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 153. ASIA-PACIFIC INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 154. ASIA-PACIFIC INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 155. ASIA-PACIFIC INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY BENZODIAZEPINES, 2018-2032 (USD MILLION)
TABLE 156. ASIA-PACIFIC INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY MELATONIN RECEPTOR AGONISTS, 2018-2032 (USD MILLION)
TABLE 157. ASIA-PACIFIC INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY NON BENZODIAZEPINE HYPNOTICS, 2018-2032 (USD MILLION)
TABLE 158. ASIA-PACIFIC INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY ZOLPIDEM, 2018-2032 (USD MILLION)
TABLE 159. ASIA-PACIFIC INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY OREXIN RECEPTOR ANTAGONISTS, 2018-2032 (USD MILLION)
TABLE 160. ASIA-PACIFIC INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY SEDATING ANTIDEPRESSANTS, 2018-2032 (USD MILLION)
TABLE 161. ASIA-PACIFIC INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
TABLE 162. ASIA-PACIFIC INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY CAPSULES, 2018-2032 (USD MILLION)
TABLE 163. ASIA-PACIFIC INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY TABLETS, 2018-2032 (USD MILLION)
TABLE 164. ASIA-PACIFIC INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY SLEEP DISORDER TYPE, 2018-2032 (USD MILLION)
TABLE 165. ASIA-PACIFIC INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 166. ASIA-PACIFIC INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2032 (USD MILLION)
TABLE 167. ASIA-PACIFIC INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY ONLINE PHARMACY, 2018-2032 (USD MILLION)
TABLE 168. ASIA-PACIFIC INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY RETAIL PHARMACY, 2018-2032 (USD MILLION)
TABLE 169. ASIA-PACIFIC INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 170. ASIA-PACIFIC INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY HOMECARE SETTINGS, 2018-2032 (USD MILLION)
TABLE 171. ASIA-PACIFIC INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
TABLE 172. ASIA-PACIFIC INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
TABLE 173. EUROPE INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 174. EUROPE INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 175. EUROPE INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY BENZODIAZEPINES, 2018-2032 (USD MILLION)
TABLE 176. EUROPE INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY MELATONIN RECEPTOR AGONISTS, 2018-2032 (USD MILLION)
TABLE 177. EUROPE INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY NON BENZODIAZEPINE HYPNOTICS, 2018-2032 (USD MILLION)
TABLE 178. EUROPE INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY ZOLPIDEM, 2018-2032 (USD MILLION)
TABLE 179. EUROPE INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY OREXIN RECEPTOR ANTAGONISTS, 2018-2032 (USD MILLION)
TABLE 180. EUROPE INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY SEDATING ANTIDEPRESSANTS, 2018-2032 (USD MILLION)
TABLE 181. EUROPE INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
TABLE 182. EUROPE INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY CAPSULES, 2018-2032 (USD MILLION)
TABLE 183. EUROPE INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY TABLETS, 2018-2032 (USD MILLION)
TABLE 184. EUROPE INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY SLEEP DISORDER TYPE, 2018-2032 (USD MILLION)
TABLE 185. EUROPE INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 186. EUROPE INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2032 (USD MILLION)
TABLE 187. EUROPE INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY ONLINE PHARMACY, 2018-2032 (USD MILLION)
TABLE 188. EUROPE INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY RETAIL PHARMACY, 2018-2032 (USD MILLION)
TABLE 189. EUROPE INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 190. EUROPE INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY HOMECARE SETTINGS, 2018-2032 (USD MILLION)
TABLE 191. EUROPE INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
TABLE 192. EUROPE INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
TABLE 193. NORTH AMERICA INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 194. NORTH AMERICA INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 195. NORTH AMERICA INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY BENZODIAZEPINES, 2018-2032 (USD MILLION)
TABLE 196. NORTH AMERICA INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY MELATONIN RECEPTOR AGONISTS, 2018-2032 (USD MILLION)
TABLE 197. NORTH AMERICA INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY NON BENZODIAZEPINE HYPNOTICS, 2018-2032 (USD MILLION)
TABLE 198. NORTH AMERICA INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY ZOLPIDEM, 2018-2032 (USD MILLION)
TABLE 199. NORTH AMERICA INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY OREXIN RECEPTOR ANTAGONISTS, 2018-2032 (USD MILLION)
TABLE 200. NORTH AMERICA INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY SEDATING ANTIDEPRESSANTS, 2018-2032 (USD MILLION)
TABLE 201. NORTH AMERICA INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
TABLE 202. NORTH AMERICA INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY CAPSULES, 2018-2032 (USD MILLION)
TABLE 203. NORTH AMERICA INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY TABLETS, 2018-2032 (USD MILLION)
TABLE 204. NORTH AMERICA INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY SLEEP DISORDER TYPE, 2018-2032 (USD MILLION)
TABLE 205. NORTH AMERICA INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 206. NORTH AMERICA INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2032 (USD MILLION)
TABLE 207. NORTH AMERICA INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY ONLINE PHARMACY, 2018-2032 (USD MILLION)
TABLE 208. NORTH AMERICA INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY RETAIL PHARMACY, 2018-2032 (USD MILLION)
TABLE 209. NORTH AMERICA INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 210. NORTH AMERICA INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY HOMECARE SETTINGS, 2018-2032 (USD MILLION)
TABLE 211. NORTH AMERICA INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
TABLE 212. NORTH AMERICA INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
TABLE 213. LATIN AMERICA INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 214. LATIN AMERICA INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 215. LATIN AMERICA INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY BENZODIAZEPINES, 2018-2032 (USD MILLION)
TABLE 216. LATIN AMERICA INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY MELATONIN RECEPTOR AGONISTS, 2018-2032 (USD MILLION)
TABLE 217. LATIN AMERICA INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY NON BENZODIAZEPINE HYPNOTICS, 2018-2032 (USD MILLION)
TABLE 218. LATIN AMERICA INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY ZOLPIDEM, 2018-2032 (USD MILLION)
TABLE 219. LATIN AMERICA INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY OREXIN RECEPTOR ANTAGONISTS, 2018-2032 (USD MILLION)
TABLE 220. LATIN AMERICA INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY SEDATING ANTIDEPRESSANTS, 2018-2032 (USD MILLION)
TABLE 221. LATIN AMERICA INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
TABLE 222. LATIN AMERICA INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY CAPSULES, 2018-2032 (USD MILLION)
TABLE 223. LATIN AMERICA INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY TABLETS, 2018-2032 (USD MILLION)
TABLE 224. LATIN AMERICA INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY SLEEP DISORDER TYPE, 2018-2032 (USD MILLION)
TABLE 225. LATIN AMERICA INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 226. LATIN AMERICA INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2032 (USD MILLION)
TABLE 227. LATIN AMERICA INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY ONLINE PHARMACY, 2018-2032 (USD MILLION)
TABLE 228. LATIN AMERICA INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY RETAIL PHARMACY, 2018-2032 (USD MILLION)
TABLE 229. LATIN AMERICA INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 230. LATIN AMERICA INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY HOMECARE SETTINGS, 2018-2032 (USD MILLION)
TABLE 231. LATIN AMERICA INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
TABLE 232. LATIN AMERICA INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
TABLE 233. AFRICA INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 234. AFRICA INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 235. AFRICA INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY BENZODIAZEPINES, 2018-2032 (USD MILLION)
TABLE 236. AFRICA INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY MELATONIN RECEPTOR AGONISTS, 2018-2032 (USD MILLION)
TABLE 237. AFRICA INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY NON BENZODIAZEPINE HYPNOTICS, 2018-2032 (USD MILLION)
TABLE 238. AFRICA INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY ZOLPIDEM, 2018-2032 (USD MILLION)
TABLE 239. AFRICA INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY OREXIN RECEPTOR ANTAGONISTS, 2018-2032 (USD MILLION)
TABLE 240. AFRICA INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY SEDATING ANTIDEPRESSANTS, 2018-2032 (USD MILLION)
TABLE 241. AFRICA INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
TABLE 242. AFRICA INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY CAPSULES, 2018-2032 (USD MILLION)
TABLE 243. AFRICA INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY TABLETS, 2018-2032 (USD MILLION)
TABLE 244. AFRICA INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY SLEEP DISORDER TYPE, 2018-2032 (USD MILLION)
TABLE 245. AFRICA INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 246. AFRICA INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2032 (USD MILLION)
TABLE 247. AFRICA INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY ONLINE PHARMACY, 2018-2032 (USD MILLION)
TABLE 248. AFRICA INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY RETAIL PHARMACY, 2018-2032 (USD MILLION)
TABLE 249. AFRICA INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 250. AFRICA INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY HOMECARE SETTINGS, 2018-2032 (USD MILLION)
TABLE 251. AFRICA INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
TABLE 252. AFRICA INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
TABLE 253. MIDDLE EAST INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 254. MIDDLE EAST INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 255. MIDDLE EAST INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY BENZODIAZEPINES, 2018-2032 (USD MILLION)
TABLE 256. MIDDLE EAST INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY MELATONIN RECEPTOR AGONISTS, 2018-2032 (USD MILLION)
TABLE 257. MIDDLE EAST INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY NON BENZODIAZEPINE HYPNOTICS, 2018-2032 (USD MILLION)
TABLE 258. MIDDLE EAST INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY ZOLPIDEM, 2018-2032 (USD MILLION)
TABLE 259. MIDDLE EAST INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY OREXIN RECEPTOR ANTAGONISTS, 2018-2032 (USD MILLION)
TABLE 260. MIDDLE EAST INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY SEDATING ANTIDEPRESSANTS, 2018-2032 (USD MILLION)
TABLE 261. MIDDLE EAST INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
TABLE 262. MIDDLE EAST INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY CAPSULES, 2018-2032 (USD MILLION)
TABLE 263. MIDDLE EAST INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY TABLETS, 2018-2032 (USD MILLION)
TABLE 264. MIDDLE EAST INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY SLEEP DISORDER TYPE, 2018-2032 (USD MILLION)
TABLE 265. MIDDLE EAST INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 266. MIDDLE EAST INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2032 (USD MILLION)
TABLE 267. MIDDLE EAST INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY ONLINE PHARMACY, 2018-2032 (USD MILLION)
TABLE 268. MIDDLE EAST INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY RETAIL PHARMACY, 2018-2032 (USD MILLION)
TABLE 269. MIDDLE EAST INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 270. MIDDLE EAST INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY HOMECARE SETTINGS, 2018-2032 (USD MILLION)
TABLE 271. MIDDLE EAST INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
TABLE 272. MIDDLE EAST INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
TABLE 273. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 274. NATO INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 275. NATO INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 276. NATO INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY BENZODIAZEPINES, 2018-2032 (USD MILLION)
TABLE 277. NATO INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY MELATONIN RECEPTOR AGONISTS, 2018-2032 (USD MILLION)
TABLE 278. NATO INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY NON BENZODIAZEPINE HYPNOTICS, 2018-2032 (USD MILLION)
TABLE 279. NATO INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY ZOLPIDEM, 2018-2032 (USD MILLION)
TABLE 280. NATO INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY OREXIN RECEPTOR ANTAGONISTS, 2018-2032 (USD MILLION)
TABLE 281. NATO INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY SEDATING ANTIDEPRESSANTS, 2018-2032 (USD MILLION)
TABLE 282. NATO INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
TABLE 283. NATO INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY CAPSULES, 2018-2032 (USD MILLION)
TABLE 284. NATO INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY TABLETS, 2018-2032 (USD MILLION)
TABLE 285. NATO INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY SLEEP DISORDER TYPE, 2018-2032 (USD MILLION)
TABLE 286. NATO INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 287. NATO INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2032 (USD MILLION)
TABLE 288. NATO INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY ONLINE PHARMACY, 2018-2032 (USD MILLION)
TABLE 289. NATO INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY RETAIL PHARMACY, 2018-2032 (USD MILLION)
TABLE 290. NATO INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 291. NATO INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY HOMECARE SETTINGS, 2018-2032 (USD MILLION)
TABLE 292. NATO INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
TABLE 293. NATO INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
TABLE 294. G7 INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 295. G7 INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 296. G7 INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY BENZODIAZEPINES, 2018-2032 (USD MILLION)
TABLE 297. G7 INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY MELATONIN RECEPTOR AGONISTS, 2018-2032 (USD MILLION)
TABLE 298. G7 INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY NON BENZODIAZEPINE HYPNOTICS, 2018-2032 (USD MILLION)
TABLE 299. G7 INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY ZOLPIDEM, 2018-2032 (USD MILLION)
TABLE 300. G7 INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY OREXIN RECEPTOR ANTAGONISTS, 2018-2032 (USD MILLION)
TABLE 301. G7 INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY SEDATING ANTIDEPRESSANTS, 2018-2032 (USD MILLION)
TABLE 302. G7 INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
TABLE 303. G7 INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY CAPSULES, 2018-2032 (USD MILLION)
TABLE 304. G7 INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY TABLETS, 2018-2032 (USD MILLION)
TABLE 305. G7 INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY SLEEP DISORDER TYPE, 2018-2032 (USD MILLION)
TABLE 306. G7 INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 307. G7 INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2032 (USD MILLION)
TABLE 308. G7 INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY ONLINE PHARMACY, 2018-2032 (USD MILLION)
TABLE 309. G7 INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY RETAIL PHARMACY, 2018-2032 (USD MILLION)
TABLE 310. G7 INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 311. G7 INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY HOMECARE SETTINGS, 2018-2032 (USD MILLION)
TABLE 312. G7 INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
TABLE 313. G7 INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
TABLE 314. BRICS INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 315. BRICS INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 316. BRICS INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY BENZODIAZEPINES, 2018-2032 (USD MILLION)
TABLE 317. BRICS INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY MELATONIN RECEPTOR AGONISTS, 2018-2032 (USD MILLION)
TABLE 318. BRICS INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY NON BENZODIAZEPINE HYPNOTICS, 2018-2032 (USD MILLION)
TABLE 319. BRICS INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY ZOLPIDEM, 2018-2032 (USD MILLION)
TABLE 320. BRICS INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY OREXIN RECEPTOR ANTAGONISTS, 2018-2032 (USD MILLION)
TABLE 321. BRICS INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY SEDATING ANTIDEPRESSANTS, 2018-2032 (USD MILLION)
TABLE 322. BRICS INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
TABLE 323. BRICS INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY CAPSULES, 2018-2032 (USD MILLION)
TABLE 324. BRICS INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY TABLETS, 2018-2032 (USD MILLION)
TABLE 325. BRICS INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY SLEEP DISORDER TYPE, 2018-2032 (USD MILLION)
TABLE 326. BRICS INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 327. BRICS INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2032 (USD MILLION)
TABLE 328. BRICS INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY ONLINE PHARMACY, 2018-2032 (USD MILLION)
TABLE 329. BRICS INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY RETAIL PHARMACY, 2018-2032 (USD MILLION)
TABLE 330. BRICS INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 331. BRICS INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY HOMECARE SETTINGS, 2018-2032 (USD MILLION)
TABLE 332. BRICS INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
TABLE 333. BRICS INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
TABLE 33

Companies Mentioned

Academics Pharmaceuticals Inc
Alembic Pharmaceuticals Ltd
Alkem Laboratories Ltd
Astellas Pharma Inc
Aurobindo Pharma Ltd
Avadel Pharmaceuticals plc
Bayer AG
Cipla Ltd
Currax Pharmaceuticals LLC
Dr Reddy's Laboratories Ltd
Eisai Co Ltd
GlaxoSmithKline plc
Glenmark Pharmaceuticals Ltd
H Lundbeck A/S
Idorsia Ltd
Jazz Pharmaceuticals plc
Lupin Ltd
Mankind Pharma Ltd
Merck & Co Inc
Novartis AG
Pfizer Inc
Procter & Gamble Health Ltd
Sanofi SA
Sumitomo Pharma Co Ltd
Sun Pharmaceutical Industries Ltd
Takeda Pharmaceutical Company Limited
Teva Pharmaceutical Industries Ltd
Torrent Pharmaceuticals Ltd
Viatris Inc
Zydus Lifesciences Ltd

Table Information

Report Attribute	Details
No. of Pages	184
Published	July 2026
Forecast Period	2026 - 2032
Estimated Market Value ( USD ) in 2026	$ 3.53 Billion
Forecasted Market Value ( USD ) by 2032	$ 5.01 Billion
Compound Annual Growth Rate	5.9%
Regions Covered	Global
No. of Companies Mentioned	30

License	Format	Properties	Price
1 - 5 USER LICENSE PDF, Excel and Online Access		This is a 1-5 user license, allowing up to five users have access to the product.	€3200EUR$3,545USD£2,711GBP €3555EUR$3,939USD£3,012GBP
ENTERPRISE LICENSE PDF, Excel and Online Access		This is an enterprise license, allowing all employees within your organization access to the product.	€4840EUR$5,363USD£4,101GBP €5378EUR$5,959USD£4,557GBP

Transformative Shifts in the Insomnia Treatment Landscape

Cumulative Impact of Artificial Intelligence

Key Regional Insights Across Global Insomnia Treatment

Key Group Insights for Insomnia Pharmacological Treatment

Key Country Insights in Insomnia Pharmacological Treatment

Actionable Recommendations for Industry Leaders

Research Methodology

Conclusion

Table of Contents

Companies Mentioned

Table Information

Related Topics

Related Reports

Insomnia Pharmacological Treatment Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2021-2031

Insomnia Market Size, Share, Trends and Forecast by Therapy Type, Drug Class, Distribution Channel, and Region, 2026-2034

Insomnia Market Report 2026

Insomnia Drugs Market - Global Forecast 2026-2032

Insomnia Market - A Global and Regional Analysis: Focus on Treatment Type, Sales Channel, Country, 2025-2035